How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Using two iPhones has always come with one obvious headache: your phone number typically belongs to one of them. You can move an eSIM between devices, use various workarounds, or simply accept that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Daniel Jassy, CFA, is an Investopedia Academy instructor and the founder of SPYderCRusher Research. He contributes to Excel and Algorithmic Trading. Dr. JeFreda R. Brown is a financial consultant, ...

AI is rewriting the world and, at the same time, inventing a whole new language to describe how it’s doing it. Sit in on any product meeting, pitch, or panel these days, and you’ll hear people toss ...

Solid-state battery specialist Factorial Energy is teaming up with Mitsui Kinzoku, one of the few companies producing sulfide-based solid electrolytes, to scale up the promising new technology.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...